{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:39:46Z","timestamp":1790199586519,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":492,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL126724"],"award-info":[{"award-number":["HL126724"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL144552"],"award-info":[{"award-number":["HL144552"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1111\/jth.15406","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T04:46:13Z","timestamp":1622522773000},"page":"1864-1871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["The standard of care for immune thrombotic thrombocytopenic purpura today"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1680-5295","authenticated-orcid":false,"given":"X. Long","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.15406_bb0010","doi-asserted-by":"crossref","first-page":"41059","DOI":"10.1074\/jbc.C100515200","article-title":"Structure of von Willebrand factor\u2010cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura","volume":"276","author":"Zheng","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15406_bb0015","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"key":"10.1111\/jth.15406_bb0020","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1182\/blood-2002-05-1401","article-title":"ADAMTS\u201013 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions","volume":"100","author":"Dong","year":"2002","journal-title":"Blood"},{"key":"10.1111\/jth.15406_bb0025","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1182\/blood.V87.10.4235.bloodjournal87104235","article-title":"Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion","volume":"87","author":"Tsai","year":"1996","journal-title":"Blood"},{"key":"10.1111\/jth.15406_bb0030","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1172\/JCI112064","article-title":"Biosynthesis of von Willebrand protein by human megakaryocytes","volume":"76","author":"Sporn","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1111\/jth.15406_bb0035","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0025-6196(12)60522-9","article-title":"von Willebrand factor and the endothelium","volume":"66","author":"Wagner","year":"1991","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 1","key":"10.1111\/jth.15406_bb0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jth.12221","article-title":"Structure\u2010function and regulation of ADAMTS\u201013 protease","volume":"11","author":"Zheng","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15406_bb0045","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura","volume":"307","author":"Moake","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15406_bb0050","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev.pathmechdis.3.121806.154311","article-title":"Pathogenesis of thrombotic microangiopathies","volume":"3","author":"Zheng","year":"2008","journal-title":"Annu Rev Pathol"},{"key":"10.1111\/jth.15406_bb0055","doi-asserted-by":"crossref","first-page":"834","DOI":"10.5858\/2003-127-834-TTPAHU","article-title":"Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases","volume":"127","author":"Hosler","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"10.1111\/jth.15406_bb0060","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15406_bb0065","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura\u2010hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15406_bb0070","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2003-11-4035","article-title":"Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"key":"10.1111\/jth.15406_bb0075","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3324\/haematol.2018.198275","article-title":"Clinical factors and biomarkers predict outcome in patients with immune\u2010mediated thrombotic thrombocytopenic purpura","volume":"104","author":"Staley","year":"2019","journal-title":"Haematologica"},{"key":"10.1111\/jth.15406_bb0080","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/01.md.0000133622.03370.07","volume":"83","author":"Coppo","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1111\/jth.15406_bb0085","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/pbc.24612","article-title":"Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features","volume":"60","author":"Reese","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1111\/jth.15406_bb0090","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15406_bb0095","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020009801","article-title":"Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura","author":"Tarasco","year":"2021","journal-title":"Blood"},{"key":"10.1111\/jth.15406_bb0100","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.3324\/haematol.2019.216796","article-title":"The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017","volume":"104","author":"Dorland","year":"2019","journal-title":"Haematologica"},{"key":"10.1111\/jth.15406_bb0105","series-title":"ADAMTS13 Biology and Disease","first-page":"73","article-title":"Hereditary deficiency of ADAMTS13 activity: Upshaw\u2010Schulman syndrome","author":"Fujimura","year":"2015"},{"issue":"Suppl 1","key":"10.1111\/jth.15406_bb0110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1538-7836.2011.04341.x","article-title":"Natural history of Upshaw\u2010Schulman syndrome based on ADAMTS13 gene analysis in Japan","volume":"9","author":"Fujimura","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15406_bb0115","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0040-1722610","article-title":"Cerebral infarction in immune thrombotic thrombocytopenic purpura is associated with old age, hypertension, smoking, and anti\u2010ADAMTS13 Ig, But Not with Mortality","volume":"5","author":"Memon","year":"2021","journal-title":"TH Open"},{"key":"10.1111\/jth.15406_bb0120","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ajh.23249","article-title":"Atypical thrombotic thrombocytopenic purpura in a middle\u2010aged woman who presented with a recurrent stroke","volume":"88","author":"Idowu","year":"2013","journal-title":"Am J Hematol"},{"issue":"1016","key":"10.1111\/jth.15406_bb0125","first-page":"e1","article-title":"Predictors of in\u2010hospital mortality and acute myocardial infarction in thrombotic thrombocytopenic purpura","volume":"126","author":"Balasubramaniyam","year":"2013","journal-title":"Am J Med"},{"key":"10.1111\/jth.15406_bb0130","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/clc.20731","article-title":"Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: a single\u2010center experience","volume":"33","author":"Gandhi","year":"2010","journal-title":"Clin Cardiol"},{"key":"10.1111\/jth.15406_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.06.2010.3113","article-title":"Coma in thrombotic thrombocytopenic purpura","volume":"2010","author":"de Jong","year":"2010","journal-title":"BMJ Case Rep"},{"key":"10.1111\/jth.15406_bb0140","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/archneurol.2010.314","article-title":"Seizure in patients with thrombotic thrombocytopenic purpura","volume":"67","author":"Pandey","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1111\/jth.15406_bb0145","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3324\/haematol.2011.049676","article-title":"Thrombotic Microangiopathies Reference C. Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency\u2010associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"97","author":"Benhamou","year":"2012","journal-title":"Haematologica"},{"key":"10.1111\/jth.15406_bb0150","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jca.21216","article-title":"A case series of atypical presentations of thrombotic thrombocytopenic purpura","volume":"27","author":"Imanirad","year":"2012","journal-title":"J Clin Apher"},{"key":"10.1111\/jth.15406_bb0155","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jca.21510","article-title":"Increased troponin I is associated with fatal outcome in acquired thrombotic thrombocytopenic purpura","volume":"32","author":"Brazelton","year":"2017","journal-title":"J Clin Apher"},{"key":"10.1111\/jth.15406_bb0160","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1538-7836.2009.03285.x","article-title":"Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13","volume":"7","author":"Hughes","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15406_bb0165","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jth.12790","article-title":"Cardiac troponin\u2010I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"13","author":"Benhamou","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15406_bb0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000513574","article-title":"Identification of biomarkers in patients with thrombotic thrombocytopenic purpura presenting with large and small ischemic stroke","volume":"11","author":"Lin","year":"2021","journal-title":"Cerebrovasc Dis Extra"},{"key":"10.1111\/jth.15406_bb0175","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/01.STR.22.8.1087","article-title":"Stroke in relapsing thrombotic thrombocytopenic purpura","volume":"22","author":"Rinkel","year":"1991","journal-title":"Stroke"},{"key":"10.1111\/jth.15406_bb0180","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/2040620715571076","article-title":"Differentiating malignant hypertension\u2010induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura","volume":"6","author":"Khanal","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"10.1111\/jth.15406_bb0185","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10641963.2010.503303","article-title":"Clinical features of malignant hypertension with thrombotic microangiopathy","volume":"33","author":"Akimoto","year":"2011","journal-title":"Clin Exp Hypertens"},{"key":"10.1111\/jth.15406_bb0190","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15406_bb0195","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1182\/blood-2005-03-1087","article-title":"Severe secondary deficiency of von Willebrand factor\u2010cleaving protease (ADAMTS13) in patients with sepsis\u2010induced disseminated intravascular coagulation: its correlation with development of renal failure","volume":"107","author":"Ono","year":"2006","journal-title":"Blood"},{"key":"10.1111\/jth.15406_bb0200","first-page":"649","article-title":"Cancer\u2010associated thrombotic microangiopathy","volume":"10","author":"Govind Babu","year":"2016","journal-title":"Ecancermedicalscience"},{"key":"10.1111\/jth.15406_bb0205","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0272-6386(96)90468-0","article-title":"Cyclosporine\u2010associated thrombotic microangiopathy\/hemolytic uremic syndrome following kidney and kidney\u2010pancreas transplantation","volume":"28","author":"Young","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/jth.15406_bb0210","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00007890-200008150-00029","article-title":"Clopidogrel\u2010associated thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome in a kidney\/pancreas transplant recipient","volume":"70","author":"Chinnakotla","year":"2000","journal-title":"Transplantation"},{"key":"10.1111\/jth.15406_bb0215","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00062752-200109000-00004","article-title":"Drug\u2010associated thrombotic thrombocytopenic purpura\u2010hemolytic uremic syndrome","volume":"8","author":"Medina","year":"2001","journal-title":"Curr Opin Hematol"},{"key":"10.1111\/jth.15406_bb0220","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1182\/blood.V93.11.3798","article-title":"von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation\u2010associated, thrombotic thrombocytopenic purpura","volume":"93","author":"Plas","year":"1999","journal-title":"Blood"},{"key":"10.1111\/jth.15406_bb0225","first-page":"126","article-title":"Transplantation\u2010associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome","volume":"34","author":"Schriber","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1111\/jth.15406_bb0230","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/096120339900800613","article-title":"Relapsing catastrophic antiphospholipid antibody syndrome: a mimic for thrombotic thrombocytopenic purpura?","volume":"8","author":"Cerveny","year":"1999","journal-title":"Lupus"},{"key":"10.1111\/jth.15406_bb0235","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2141.2009.08043.x","article-title":"The difficult distinction between antiphospholipid syndrome and thrombotic thrombocytopenic purpura","volume":"149","author":"Thachil","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15406_bb0240","doi-asserted-by":"crossref","first-page":"E64","DOI":"10.1002\/ajh.25363","article-title":"Fat embolism syndrome due to bone marrow necrosis in patients with hemoglobinopathies: a life\u2010threatening complication mimicking thrombotic thrombocytopenic purpura","volume":"94","author":"Gangaraju","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.15406_bb0245","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ajh.23840","article-title":"Bone marrow necrosis discovered in a patient with suspected thrombotic thrombocytopenic purpura","volume":"90","author":"Parekh","year":"2015","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1111\/jth.15406_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010208","article-title":"French Reference Center for Thrombotic M. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"10.1111\/jth.15406_bb0255","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1111\/jth.15406_bb0260","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/bjh.15932","article-title":"Utilizing a PLASMIC score\u2010based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA Research Collaborative","volume":"186","author":"Upadhyay","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15406_bb0265","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1111\/trf.14230","article-title":"ADAMTS13 test and\/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost\u2010effective analysis","volume":"57","author":"Kim","year":"2017","journal-title":"Transfusion"},{"key":"10.1111\/jth.15406_bb0270","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/trf.15954","article-title":"Diagnostic accuracy of the PLASMIC score in patients with suspected thrombotic thrombocytopenic purpura: A systematic review and meta\u2010analysis","volume":"60","author":"Paydary","year":"2020","journal-title":"Transfusion"},{"key":"10.1111\/jth.15406_bb0275","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.thromres.2020.09.012","article-title":"Validation of the PLASMIC score for predicting ADAMTS13 activity <10% in patients with suspected thrombotic thrombocytopenic purpura in Alberta, Canada","volume":"196","author":"Wynick","year":"2020","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15406_bb0280","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15406_bb0285","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/asheducation-2016.1.217","article-title":"Atypical hemolytic uremic syndrome","volume":"2016","author":"Afshar\u2010Kharghan","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1111\/jth.15406_bb0290","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/jth.13764","article-title":"Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics","volume":"15","author":"Saha","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15406_bb0295","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/jth.13922","article-title":"An open conformation of ADAMTS\u201013 is a hallmark of acute acquired thrombotic thrombocytopenic purpura","volume":"16","author":"Roose","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15406_bb0300","first-page":"353","article-title":"Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune\u2010mediated thrombotic thrombocytopenic purpura","volume":"136","author":"Roose","year":"2020","journal-title":"Blood"},{"key":"10.1111\/jth.15406_bb0305","doi-asserted-by":"crossref","DOI":"10.1111\/jth.15332","article-title":"A human monoclonal antibody against the distal carboxyl terminus of ADAMTS13 modulates its susceptibility to an inhibitor in thrombotic thrombocytopenic purpura","author":"Halkidis","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15406_bb0310","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1182\/bloodadvances.2019000939","article-title":"Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura","volume":"3","author":"Sui","year":"2019","journal-title":"Blood Adv"},{"key":"10.1111\/jth.15406_bb0315","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2141.2005.05837.x","article-title":"Prognostic value of inhibitory anti\u2010ADAMTS13 antibodies in adult\u2010acquired thrombotic thrombocytopenic purpura","volume":"132","author":"Coppo","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15406_bb0320","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1600-0609.2012.01767.x","article-title":"Long\u2010term management of acquired thrombotic thrombocytopenic purpura using serial plasma ADAMTS13 measurements","volume":"88","author":"Knovich","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1111\/jth.15406_bb0325","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood-2006-02-006064","volume":"109","author":"Ferrari","year":"2007","journal-title":"Blood"},{"key":"10.1111\/jth.15406_bb0330","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15406_bb0335","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for congenital atypical hemolytic\u2010uremic syndrome","volume":"360","author":"Gruppo","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15406_bb0340","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2010uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15406_bb0345","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/jth.15194","article-title":"Should all patients with immune\u2010mediated thrombotic thrombocytopenic purpura receive caplacizumab?","volume":"19","author":"Picod","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15406_bb0350","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune\u2010mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"key":"10.1111\/jth.15406_bb0355","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF00921009","article-title":"Steroids, aspirin, and inflammation","volume":"2","author":"Katler","year":"1977","journal-title":"Inflammation"},{"issue":"Suppl 1","key":"10.1111\/jth.15406_bb0360","first-page":"S88","article-title":"Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura","volume":"87","author":"George","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.15406_bb0365","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15406_bb0370","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.15406_bb0375","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15406_bb0380","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","article-title":"Real\u2010world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"4","author":"Volker","year":"2020","journal-title":"Blood Adv"},{"key":"10.1111\/jth.15406_bb0385","article-title":"Real\u2010world evidence of caplacizumab use in the management of acute TTP","author":"Dutt","year":"2020","journal-title":"Blood"},{"key":"10.1111\/jth.15406_bb0390","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/blood.2020009250","article-title":"Counting the cost of caplacizumab","volume":"137","author":"Chaturvedi","year":"2021","journal-title":"Blood"},{"key":"10.1111\/jth.15406_bb0395","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ajh.24060","article-title":"Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura","volume":"90","author":"Han","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.15406_bb0400","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2019001056","article-title":"Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors","volume":"134","author":"Upreti","year":"2019","journal-title":"Blood"},{"key":"10.1111\/jth.15406_bb0405","first-page":"43","article-title":"Cost\u2010effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in Italy","volume":"8","author":"Di Minno","year":"2021","journal-title":"Glob Reg Health Technol Assess"},{"key":"10.1111\/jth.15406_bb0410","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"key":"10.1111\/jth.15406_bb0415","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1111\/jth.15045","article-title":"Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab","volume":"18","author":"Volker","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15406_bb0420","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1182\/blood.2020009654","article-title":"TTP: the evolution of clinical practice","volume":"137","author":"George","year":"2021","journal-title":"Blood"},{"key":"10.1111\/jth.15406_bb0425","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/trf.15823","article-title":"Caplacizumab for treatment of thrombotic thrombocytopenic purpura in a patient with anaphylaxis to fresh\u2010frozen plasma","volume":"60","author":"Irani","year":"2020","journal-title":"Transfusion"},{"key":"10.1111\/jth.15406_bb0430","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMc1905426","article-title":"Caplacizumab therapy without plasma exchange for acquired thrombotic thrombocytopenic purpura","volume":"381","author":"Chander","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15406_bb0435","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS\u201013: first\u2010in\u2010human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"key":"10.1111\/jth.15406_bb0440","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1538-7836.2011.04224.x","article-title":"Recombinant ADAMTS13 normalizes von Willebrand factor\u2010cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies","volume":"9","author":"Plaimauer","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15406_bb0445","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1182\/blood-2011-12-399501","article-title":"Gain\u2010of\u2010function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura","volume":"119","author":"Jian","year":"2012","journal-title":"Blood"},{"issue":"19","key":"10.1111\/jth.15406_bb0450","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1182\/blood.2020007972","article-title":"N\u2010glycan mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune\u2010mediated TTP","volume":"137","author":"Ercig","year":"2021","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15406","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15406","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622018633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622018633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:33:36Z","timestamp":1761536016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622018633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":89,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1538783622018633"],"URL":"https:\/\/doi.org\/10.1111\/jth.15406","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The standard of care for immune thrombotic thrombocytopenic purpura today","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15406","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}